This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: American Heart Association

News from the American Heart Association Scientific Sessions 2013

February 2014 Br J Cardiol 2014;21:10–11 Online First

News from the American Heart Association Scientific Sessions 2013

BJCardio Staff

Abstract

ENGAGE AF-TIMI 48: success for edoxaban in AF The new factor Xa inhibitor, edoxaban (Daiichi-Sankyo), was as effective in preventing strokes and safer than warfarin in patients with atrial fibrillation (AF) in the ENGAGE AF-TIMI 48 trial. The ENGAGE AF-TIMI 48 (Effective AnticoaGulation with Factor XA Next Generation in Atrial Fibrillation – Thrombolysis In Myocardial Infarction 48) trial included more than 21,000 AF patients from 46 countries who were randomised to edoxaban at one of two doses (60 mg or 30 mg per day) or warfarin. Results (table 1) showed that both edoxaban doses were associated with significantly less major bleeding than

| Full text

December 2012 Br J Cardiol 2013;20:14–5 Online First

News from the American Heart Association Scientific Sessions 2012

BJCardio Staff

Abstract

FREEDOM: CABG beats PCI in diabetes patients with multi-vessel disease Coronary artery by-pass graft (CABG) surgery was associated with better outcomes than percutaneous coronary intervention (PCI) in patients with diabetes with multi-vessel coronary artery disease in the FREEDOM (Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multi-vessel Disease) trial. Senior FREEDOM investigator, Dr Valentin Fuster (Mount Sinai School of Medicine, New York, USA), said the results (table 1) would change practice. He estimated that patients in this study represent about a quarter of patients undergoing PCI. In

| Full text
News from the American Heart Association Scientific Sessions 2010

February 2011 Br J Cardiol 2011;18:11-3

News from the American Heart Association Scientific Sessions 2010

Abstract

Highlights of the American Heart Association 2010 meeting held in November 2010, in Chicago, USA, included a breakthrough for the treatment of resistant hypertension, and another oral anticoagulant that could be used instead of warfarin in atrial fibrillation patients, without the need for monitoring. RAFT: CRT reduces deaths and hospitalisations in mild heart failure Adding cardiac-resynchronisation therapy (CRT) to implantable cardioverter defibrillator (ICD) and medication, led to a reduction in deaths and heart failure hospitalistions among patients with mild-to-moderate symptoms of heart failure in the RAFT (Resynchronisation-Defibrilla

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now